ERCC2 and colorectal carcinoma: In a study of 106 evaluable patients with advanced CRC who were treated with an OX/5-FU regimen as a second-line treatment, the impact of XPD 751 polymorphism was measured in PFS and OS (Stoehlmacher et al, 2004).